```
=> d ibib abs hitstr 15 1-44
THE ESTIMATED COST FOR THIS REQUEST IS 248.16 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L5   ANSWER 1 OF 44  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2009:739059  CAPLUS
TITLE:                    Combinations of therapeutic agents comprising vascular
                          disrupting agent such as
                          5,6-dimethylxanthenone-4-acetic acid, for treating
                          cancer
INVENTOR(S):              Evans, Dean Brent; Jacques, Christian J.
PATENT ASSIGNEE(S):       Novartis A.-G., Switz.
SOURCE:                   PCT Int. Appl., 57pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    -------------------    --------
     WO 2009076170        A2    20090618    WO 2008-US85535        20081204
          W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
              CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
              FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
              KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
              ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
              PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
              TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
          RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
              IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
              TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
              TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
              AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                        US 2007-13335P      P  20071213
AB   The invention relates to a combination comprising vascular disrupting
     agent (VDA), such as 5,6-dimethylxanthenone-4-acetic acid or a
     pharmaceutically acceptable salt, ester or prodrug thereof; and one or
     more pharmaceutically active agents; pharmaceutical compns. comprising
     said combination; methods of treatment comprising said combination;
     processes for making said combination; and a com. package comprising said
     combination.  Thus, the effects of 5,6-dimethylxanthenone-4-acetic acid
     (Compound A), trastuzumab and paclitaxel are evaluated for their antitumor
     activity using the BT-474 human breast ductal carcinoma xenograft model;
     the data shows that Compound A at 20 mg/kg given i.v. on days 1, 5 and 9 is
     able to produce inhibition of tumor growth; paclitaxel combined with
     trastuzumab is also active resulting in a combination effect; when Compound
     A at 20 mg/kg is combined with paclitaxel and trastuzumab, increased
     activity is apparent resulting in tumor regressions; using the Clark
     Combination Index method, synergy is indicated; the tolerability of the
     triple combinations is no worse than that observed when Compound A is dosed
     alone.
IT   85622-93-1, Temozolomide 212141-54-3
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (synergistic combinations of therapeutic agents comprising vascular
        disrupting agent such as 5,6-dimethylxanthenone-4-acetic acid, for
        treating cancer)
RN   85622-93-1  CAPLUS
CN   Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide,
     3,4-dihydro-3-methyl-4-oxo-  (CA INDEX NAME)
```



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:519479 CAPLUS
DOCUMENT NUMBER: 150:492909
TITLE: Human anti-VEGF antibodies and conjugates for treatment of angiogenesis conditions
INVENTOR(S): Ramachandra, Sumant; Bishop, Robert Walter; Masat, Linda; Huang, Chao Bai; Takeuchi, Toshihiko; Kantak, Seema
PATENT ASSIGNEE(S): Schering Corporation, USA; Xoma Technology Ltd.
SOURCE: PCT Int. Appl., 195pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009055343	A2	20090430	WO 2008-US80531	20081020

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-981808P P 20071022
US 2008-46370P P 20080418

AB Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: BSU (Biological study, unclassified); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human anti-VEGF antibodies and conjugates for diagnosis and treatment of angiogenesis conditions)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:364201 CAPLUS
DOCUMENT NUMBER: 150:374299
TITLE: Preparation of novel fused tetrahydropyridines as inhibitors of histone deacetylases
INVENTOR(S): Maier, Thomas; Beckers, Thomas; Baer, Thomas; Vennemann, Matthias; Gekeler, Volker; Zimmermann, Astrid; Gimmnich, Petra; Padiya, Kamlesh J.; Joshi, Hemant; Joshi, Uday; Makhija, Mahindra
PATENT ASSIGNEE(S): 4SC AG, Germany
SOURCE: PCT Int. Appl., 346pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009037001	A2	20090326	WO 2008-EP8208	20080919
WO 2009037001	A3	20090507		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:		
EP 2007-116791	A	20070919
IN 2007-MU1819	A	20070919
IN 2008-MU616	A	20080324

OTHER SOURCE(S): MARPAT 150:374299

GI



I



II

AB Title compds. I [A = alkyl, alkoxy-alkyl, alkylthio-alkyl, mono- or dialkylamino-alkyl, (un)substituted cycloalkyl, etc.; L = bond, (CH2)nS(O)2, C(O), C(S), (CH2)nOC(O), etc.; B = H, halo, alkyl, alkoxy, thienyl, etc.; n = 0-2; ring D and ring E together form a fused tetrahydropyridine ring including (un)substituted thiazolopyridine, thiophenpyridine, pyrrolopyridine, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of histone deacetylases. Thus, e.g., II was prepared in 9 steps starting from di-Et oxalate. Selected compds. of the invention were evaluated for their HDAC inhibitory activity with IC50 value of > 10 nM.

IT 85622-93-1, Temodar 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of novel fused tetrahydropyridine compds. as HDAC inhibitors useful in treatment and prophylaxis of HDAC-related diseases)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:332545 CAPLUS
DOCUMENT NUMBER: 150:345478
TITLE: Compositions and methods using Stat3 pathway inhibitors or cancer stem cell inhibitors for combination cancer treatment
INVENTOR(S): Li, Chiang Jia; Mikule, Keith; Li, Youzhi
PATENT ASSIGNEE(S): Boston Biomedical, Inc., USA
SOURCE: PCT Int. Appl., 81pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009036101	A1	20090319	WO 2008-US75906	20080910
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2007-971144P P 20070910

US 2007-13372P P 20071213

AB The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Stat3 pathway inhibitors or cancer stem cell inhibitors for combination cancer treatment)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:86451 CAPLUS
DOCUMENT NUMBER: 150:160095
TITLE: Use of adenosine A2A receptor agonists and phosphodiesterase (PDE) inhibitors for the treatment

of B-cell proliferative disorders, and combinations with other agents

INVENTOR(S): Rickles, Richard; Lee, Margaret S.

PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA

SOURCE: PCT Int. Appl., 70pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009011893	A2	20090122	WO 2008-US8758	20080717
WO 2009011893	A3	20090319		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20090053168	A1	20090226	US 2008-175219	20080717
PRIORITY APPLN. INFO.:			US 2007-950307P	P 20070717
			US 2007-965587P	P 20070821

AB The invention provides compns. and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compns. may further include an antiproliferative compound

IT 85622-93-1, Temodar 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2A receptor agonists and phosphodiesterase inhibitors for treatment of B-cell proliferative disorders, and combinations with other agents)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:83374 CAPLUS
DOCUMENT NUMBER: 150:160094
TITLE: Combinations for the treatment of B-cell proliferative disorders
INVENTOR(S): Rickles, Richard; Pierce, Laura; Lee, Margaret S.
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 79pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009011897	A1	20090122	WO 2008-US8764	20080717
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090047243	A1	20090219	US 2008-175121	20080717

PRIORITY APPLN. INFO.: US 2007-959877P P 20070717
US 2007-965595P P 20070821

AB The invention features compns. and methods employing combinations of an A2A receptor agonist and a PDE (phosphodiesterase) inhibitor for the treatment of a B-cell proliferative disorder, e g, multiple myeloma. In at least one embodiment, the compns. of the invention comprise a PDE

inhibitor active against at least two of PDE 2, 3,4, and 7. In at least one embodiment, the compns. of the invention comprises further administering an antiproliferative compound

IT 85622-93-1, Temodar 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations for treatment of B-cell proliferative disorders using PDE inhibitors and A2A receptor agonists and antiproliferative compds.)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:25215 CAPLUS
DOCUMENT NUMBER: 150:119716
TITLE: Anti-insulin-like growth factor 1 receptor therapy
INVENTOR(S): Wang, Yan; Pachter, Jonathan A.; Hailey, Judith Anne; Brams, Peter; Williams, Denise; Srinivasan, Mohan;

Feingersh, Mary Diane
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 129pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009005673	A1	20090108	WO 2008-US7920	20080625

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-946803P P 20070628

AB The authors disclose the preparation and functional characterization of human antibodies to the type 1 insulin-like growth factor receptor. In one example, the growth of a human neuroblastoma was shown to be inhibited by an anti-IGF1R antibody in a xenograft model.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination therapy with anti-IGF1R antibodies)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1248933 CAPLUS
DOCUMENT NUMBER: 149:448428
TITLE: Preparation and use of quinazoline derivative for treatment of cancer
INVENTOR(S): Laughlin, Mark; Anderson, Mark B.; Willardsen, Adam; Pleiman, Chris
PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA
SOURCE: PCT Int. Appl., 24pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008124826	A1	20081016	WO 2008-US59910	20080410

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-910944P P 20070410
OTHER SOURCE(S): CASREACT 149:448428
AB This document discloses the use of a compound for the manufacture of a medicament

useful in treating cancer in a mammal in need of such treatment, comprising administering to the mammal an effective amount of N-(4-methoxyphenyl)-N,2-dimethyl-4-quinazolinamine hydrochloride (I), or a pharmaceutically acceptable salt or solvate thereof, and an effective amount of one or more chemotherapeutic agents chosen from antiangiogenic agents and cytotoxic agents. I was prepared in a 2-step process from 2-methyl-4(3H)-quinazolinone. The vascular disruption effect of I was demonstrated in mice. I was tested in a phase I clin. trial. Formulations are given.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination therapy; preparation and use of quinazoline derivative for treatment of cancer)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:804316 CAPLUS
DOCUMENT NUMBER: 149:128822
TITLE: Preparation of 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide as well as prodrugs and salts for treating cancer
INVENTOR(S): Smith, Roger; Nagarathnam, Dhanapalan
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 84pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008079968	A1	20080703	WO 2007-US88365	20071220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	US 2006-875830P	P 20061220
	US 2007-986773P	P 20071109

GI



I

AB The title compound I and alternative forms thereof (e.g., salts, solvates, hydrates, prodrugs, polymorphs and metabolites), were prepared and formulated. For example, a multi-step synthesis of I, starting from 3-hydrazinobenzoic acid and 4,4-dimethyl-3-oxopentanenitrile, was given. I showed IC50 of < 500 nM in biochem. assays for Flk-1, c-Met, wild type Bcr-Abl and mutant T315I Bcr-Abl. Also, I and derivs. thereof showed antiproliferative properties (IC50 < 5 μM) in one or more cell lines of interest. Pharmaceutical compns. which contain I and its alternative forms, and methods for treating cancer, were disclosed.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of novel Ph pyrazolyl ureas for treating cancer)
RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:796822 CAPLUS
DOCUMENT NUMBER: 149:128848
TITLE: Preparation of 5-cyano-4-(pyrrolo[2,3-b]pyridin-3-yl)pyrimidines as polo-like kinase (PLK) inhibitors.
INVENTOR(S): Mortimore, Michael; Young, Stephen Clinton; Everitt, Simon Robert Lorrie; Knegtel, Ronald; Pinder, Joanne Louise; Rutherford, Alistair Peter; Durrant, Steven; Brenchley, Guy; Charrier, Jean Damien; O'Donnell,

Michael
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 191pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008079346	A1	20080703	WO 2007-US26190	20071221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	US 2006-876307P	P 20061221
	US 2007-922291P	P 20070406
	US 2007-947707P	P 20070703
	US 2007-989014P	P 20071119

OTHER SOURCE(S): MARPAT 149:128848
GI



I

AB Title compds. [I; R1 = H, halo, (substituted) aliphatyl, aliphatyloxy; R2 = NR4R5, OR6, SR6, etc.; R4 = H, (substituted) aliphatyl; R5 = (substituted) aliphatyl, mono- or bicyclyl; R4R5 = atoms to form (substituted) mono- or bicyclyl; R6 = H, (substituted) alkyl, aryl(alkyl), heteroaryl(alkyl)], were prepared Thus, 2-methylsulfonyl-4-(1-tosyl-5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carbonitrile (preparation given) was microwaved with PhCH2NH2 and diisopropylamine in THF at 100° for 10 min. to give a residue which was stirred with LiOH in THF/H2O for 1 h to give 36% 2-benzylamino-4-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carbonitrile. I inhibited PLK1 with Ki in the range of <3 nM to >40 nM.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of cyanopyrrolopyridinylpyrimidines as polo-like kinase inhibitors)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:771165 CAPLUS
DOCUMENT NUMBER: 149:102715
TITLE: Methods of treating cancer using IGF1R inhibitors
INVENTOR(S): Wang, Yan; Zong, Chen; Seidel-Dugan, Cynthia; Wang, Yaolin; Yao, Siu-Long; Lu, Brian Der-Hua; Ladha, Mohamed H.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 103pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008076278	A2	20080626	WO 2007-US25398	20071211
WO 2008076278	A3	20090507		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:			
	US 2006-874589P	P	20061213
	US 2006-870937P	P	20061220
	US 2007-946011P	P	20070625
	US 2007-979274P	P	20071011

AB The present invention provides IGF1R inhibitors and combinations thereof that are effective at treating or preventing cancer. More specifically the IGF1R inhibitors are pyrrolo[2,3-d]pyrimidine derivs. or antibodies. The IGF1R inhibitors can be used in combination with other anticancer therapies, antiemetic agents, antianemic agents, or antimucositis agents.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; methods of treating cancer using IGF1R inhibitors)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:702849 CAPLUS
DOCUMENT NUMBER: 149:54012
TITLE: Preparation of substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives for treating hyper-proliferative disorders and diseases associated with angiogenesis
INVENTOR(S): Hentemann, Martin; Wood, Jill; Scott, William; Michels, Martin; Campbell, Ann-Marie; Bullion, Ann-Marie; Rowley, R. Bruce; Redman, Aniko
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 132pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008070150	A1	20080612	WO 2007-US24985	20071205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2006-873090P P 20061205
OTHER SOURCE(S): MARPAT 149:54012
GI



I



II

AB This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compds. I [R1 = (CH2)n(CHR4)(CH2)mNR5R51; R2 = substituted heteroaryl; R3 = alkyl or cycloalkyl; R4 = H, OH or alkoxy; R5, R51 = H, alkyl, cycloalkylalkyl, alkoxyalkyl; or NR5R51 = 3-7 membered heterocyclyl optionally containing at least one addnl. heteroatom selected from O, N or S; or R4 and R5 may be taken together with the atoms to which they are bound to form a 5-6 membered N containing heterocyclyl optionally containing 1 or more N, O or S atoms; n = 1-4; m = 0-4, with the proviso], pharmaceutical compns. containing such compds. and the use of those compds. or compns. for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. Over one-hundred compds. I were prepared E.g., a multi-step synthesis of II, starting from vanillin acetate, was given. Exemplified compds. I were tested in PI3Kα kinase assay (data given).

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of substituted 2,3-dihydroimidazo[1,2-c]quinazolines as PI3K inhibitors for treating and preventing diseases-mediated by PI3K)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:589402 CAPLUS
DOCUMENT NUMBER: 148:529419
TITLE: Methods and compositions for detecting receptor ligand mimetics
INVENTOR(S): Khazak, Vladimir; Weber, Lutz
PATENT ASSIGNEE(S): Alphaptose G.m.b.H., Germany
SOURCE: PCT Int. Appl., 53pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008055995	A2	20080515	WO 2007-EP62177	20071109
WO 2008055995	A3	20081016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2007316587 A1 20080515 AU 2007-316587 20071109

PRIORITY APPLN. INFO.: US 2006-858033P P 20061110

WO 2007-EP62177 W 20071109

AB A method to determine the utility of small mols. as functional replacements (mimetics) for protein receptor ligands is described. The method uses cellular biol. assays on a systematic array of compds., comprising known protein receptor ligands and other biol. active mols. to determine if a proposed small mol. is a functional equivalent of a receptor ligand having therapeutic utility as a pharmaceutically relevant and useful agent, either alone or in combination with other mols.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for detecting receptor ligand mimetics)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:501397 CAPLUS
DOCUMENT NUMBER: 148:495976
TITLE: Preparation of pyridonecarboxamide derivatives for treating hyper-proliferative and angiogenesis disorders
INVENTOR(S): Boyer, Stephen; Cantin, David; Liang, Sidney X.
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 72pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008048375	A1	20080424	WO 2007-US11981	20070518
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2652417	A1	20080424	CA 2007-2652417	20070518
EP 2023926	A1	20090218	EP 2007-861312	20070518
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: US 2006-801700P P 20060519

WO 2007-US11981 W 20070518

OTHER SOURCE(S): MARPAT 148:495976

GI



I



II

AB The title compds. I [X = O or S; Y and Z = CH or N; R1 = H, halo, CN, etc.; R2 = H, halo, alkoxy, etc.; R3, R4 = H, halo, CN, etc.; R5 = H, (un)substituted OH, NH2, etc.; R6 = H, alkoxy, (un)substituted NH2, etc.], useful for treating hyper-proliferative disorders and angiogenesis disorders, were prepared and formulated. E.g., a multi-step synthesis of II, starting from 2-amino-4,5-dimethoxyacetophenone, was given. Compds. I were tested in Flk-1, c-Met and Bcr-Abl assays and showed IC50 of <3 μM in one or more of the these assays.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of novel pyridonecarboxamides for use in mono- and combination therapy of hyperproliferative and angiogenesis disorders)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:380887 CAPLUS
DOCUMENT NUMBER: 148:394375
TITLE: Method for treating cancer harboring EGFR mutations
INVENTOR(S): Solca, Flavio
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 60pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008034776	A1	20080327	WO 2007-EP59735	20070914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2007299080	A1	20080327	AU 2007-299080	20070914
CA 2663599	A1	20080327	CA 2007-2663599	20070914
EP 2068880	A1	20090617	EP 2007-820235	20070914
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

KR 2009074202 A 20090706 KR 2009-707757 20070914
PRIORITY APPLN. INFO.: EP 2006-120856 A 20060918
EP 2007-101505 A 20070131
WO 2007-EP59735 W 20070914

AB The present invention relates to a method of treatment of patients suffering from cancer and harboring mutations of EGFR in the tumor, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and/or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effective amount of the irreversible EGFR inhibitor BIBW2992 (4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline), to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and/or tumor resection by surgery, and to the use of a BIBW2992 for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harboring mutations of EGFR in the tumor.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treating cancer harboring EGFR mutations using BIBW2992 in combination with other chemotherapeutic agents)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:352486 CAPLUS
DOCUMENT NUMBER: 148:355645
TITLE: Preparation of novel tetrahydroisoquinoline compounds useful in prevention, mono- and combination therapy of various diseases
INVENTOR(S): Weber, Lutz; Khazak, Vladimir; Ross, Gunther; Kalinski, Cedric; Burdack, Christoph
PATENT ASSIGNEE(S): Nexuspharma Inc., USA
SOURCE: PCT Int. Appl., 42pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008034039	A2	20080320	WO 2007-US78464	20070914
WO 2008034039	A3	20081211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: US 2006-845095P P 20060915
OTHER SOURCE(S): MARPAT 148:355645

GI



I

AB The present invention provides a compound I [X = C(O); R1 = (un)substituted morpholino, pyrrolidino, piperazino, etc.; R2 = heteroaryl, R3 = aryl, heteroaryl, arylalkyl or heteroarylalkyl; R4 = H, F, Cl, Br, I, NO2, etc.] as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compds. I can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compds. I can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections. General procedure for the synthesis of compds. I was given. Several compds. I such as 2-(4-chlorobenzyl)-3-(5-chlorothiophen-2-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid (2-methoxyethyl)amide, were prepared Pharmaceutical compns. comprising compound I alone or in combination with other therapeutic agents were disclosed.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of novel tetrahydroisoquinoline compds. useful in prevention, mono- and combination therapy of various diseases)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:72093 CAPLUS
DOCUMENT NUMBER: 148:168712
TITLE: 3-Benzoylamino-1H-pyrazole-4-carboxamides as CDK kinase inhibitors, and their preparation, pharmaceutical combinations and use in the treatment of proliferative diseases
INVENTOR(S): Lyons, John Francis; Squires, Matthew Simon; Thompson, Neil Thomas; Gallagher, Neil James
PATENT ASSIGNEE(S): Astex Therapeutics Limited, UK
SOURCE: PCT Int. Appl., 292pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008007122	A2	20080117	WO 2007-GB2654	20070713
WO 2008007122	A3	20080306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 2046330	A2	20090415	EP 2007-733530	20070713
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2006-830968P P 20060714
GB 2006-14457 A 20060720
WO 2007-GB2654 W 20070713

OTHER SOURCE(S): MARPAT 148:168712

GI



I



II

AB The invention provides a combination comprising an ancillary compound and a compound having the formula I: or salts or tautomers or N-oxides or solvates thereof/. Compds. of formula I wherein X is 5- to 6-membered (hetero/carbo)cyclic ring, amino, acylamino, sulfonylamino, etc.; Y is a bond and C1-3 alkylene; R2 is H, halo, C1-4 alkoxy, (un)substituted C1-4 hydrocarbyl; R3 is H, 3- to 12-membered (hetero/carbo)cyclic group; and their salts, tautomers, N-oxides and solvates thereof, are claimed. Example compound II•MsOH was prepared by esterification of 4-nitropyrazole-3-carboxylic acid; the resulting 4-nitropyrazole-3-carboxylic acid Me ester underwent hydrogenation to give 4-aminopyrazole-3-carboxylic acid Me ester, which underwent amidation with 2,6-dichlorobenzoyl chloride to give 4-(2,6-dichlorobenzoylamino)pyrazole-3-carboxylic acid Me ester, which underwent hydrolysis to give 4-(2,6-dichlorobenzoylamino)pyrazole-3-carboxylic acid, which underwent chlorination to give the corresponding acid chloride, which underwent amidation with 4-amino-1-Boc-piperidine to give 1-Boc-piperidin-4-yl 4-(2,6-dichlorobenzoylamino)pyrazole-3-carboxamide, which underwent hydrolysis to give compound II•MsOH. All the invention compds. were evaluated for their CDK kinase inhibitory activity (some data given).

IT 85622-93-1 212141-54-3
RL: DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of benzoylaminopyrazolecarboxamides as CDK kinase inhibitors useful in the treatment of proliferative diseases)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:43490 CAPLUS
DOCUMENT NUMBER: 148:135980
TITLE: Blood levels of insulin-like growth factor-binding protein 2 as a marker for monitoring the effectiveness of inhibitors of insulin-like growth factor I receptors in cancer therapy
INVENTOR(S): Wang, Yan
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 133pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008005469	A2	20080110	WO 2007-US15423	20070629
WO 2008005469	A3	20080228		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

CA 2655997 A1 20080110 CA 2007-2655997 20070629
US 20080112888 A1 20080515 US 2007-771454 20070629
EP 2032989 A2 20090311 EP 2007-810179 20070629
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
PRIORITY APPLN. INFO.: US 2006-818004P P 20060630
WO 2007-US15423 W 20070629

AB The present invention provides method for quickly and conveniently determining if a given treatment regimen of insulin-like growth factor I receptor (IGF1R) inhibitor is sufficient, e.g., to saturate IGF1 R receptors in the body of a subject. Blood levels of insulin-like growth factor-binding protein 2 (IGFBP2) are shown to be strongly correlated with the effectiveness of IGF1R receptor therapy. Several clin. relevant detns. may be made based on this point, including, for example, whether the dosage of the regimen is sufficient or should be increased. The relationship is demonstrated using animal xenograft models of neuroblastoma. Treatment with monoclonal antibodies to IGFR1 lowered the blood levels of IGFBP2. The level of IGFBP2 correlated with the tumor size.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer therapy using; blood levels of IGBP2 as marker for monitoring effectiveness of inhibitors of IGF1 receptors in cancer therapy)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 19 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1369348 CAPLUS
DOCUMENT NUMBER: 148:115545
TITLE: Chemoradiotherapy in malignant glioma: standard of care and future directions
AUTHOR(S): Stupp, Roger; Hegi, Monika E.; Gilbert, Mark R.; Chakravarti, Arnab
CORPORATE SOURCE: Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switz.
SOURCE: Journal of Clinical Oncology (2007), 25(26), 4127-4136
CODEN: JCONDN; ISSN: 0732-183X
PUBLISHER: American Society of Clinical Oncology
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Glioma has been considered resistant to chemotherapy and radiation. Recently, concomitant and adjuvant chemoradiotherapy with temozolomide has become the standard treatment for newly diagnosed glioblastoma. Conversely (neo-)adjuvant PCV (procarbazine, lomustine, vincristine) failed to improve survival in the more chemoresponsive tumor entities of anaplastic oligoastrocytoma and oligodendroglioma. Preclin. investigations suggest synergism or additivity of radiotherapy and temozolomide in glioma cell lines. Although the relative contribution of the concomitant and the adjuvant chemotherapy, resp., cannot be assessed, the early introduction of chemotherapy and the simultaneous administration with radiotherapy appear to be key for the improvement of outcome. Epigenetic inactivation of the DNA repair enzyme methylguanine methyltransferase (MGMT) seems to be the strongest predictive marker for outcome in patients treated with alkylating agent chemotherapy. Patients whose tumors do not have MGMT promoter methylation are less likely to benefit from the addition of temozolomide chemotherapy and require alternative treatment strategies. The predictive value of MGMT gene promoter methylation is being validated in ongoing trials aiming at overcoming this resistance by a dose-aense continuous temozolomide administration or in combination with MGMT inhibitors. Understanding of mol. mechanisms allows for rational targeting of specific pathways of

repair, signaling, and angiogenesis. The addition of tyrosine kinase inhibitors vatalanib (PTK787) and vandetinib (ZD6474), the integrin inhibitor cilengitide, the monoclonal antibodies bevacizumab and cetuximab, the mammalian target of rapamycin inhibitors temsirolimus and everolimus, and the protein kinase C inhibitor enzastaurin, among other agents, are in clin. investigation, building on the established chemoradiotherapy regimen for newly diagnosed glioblastoma.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of chemoradiotherapy in treatment of glioblastoma)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:980736 CAPLUS
DOCUMENT NUMBER: 147:371675
TITLE: Antitumor sustained-release composition containing angiogenesis inhibitors and their synergists

INVENTOR(S): Sun, Juan; Liu, Yuyan; Kong, Qingxin
PATENT ASSIGNEE(S): Jinan Kangquan Pharmaceutical Science and Technology Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 31pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101023929	A	20070829	CN 2007-10200438	20070412
PRIORITY APPLN. INFO.:			CN 2007-10200438	20070412

AB The title sustained-release composition is composed of sustained-release microspheres comprising effectively antitumor ingredients 0.5-70, sustained-release adjuvant 30-99, suspending agent 0.0-30%, and solvent. The effectively antitumor ingredients contain angiogenesis inhibitors and/or their synergists selected from antitumor antibiotics and/or tetrazine drugs. The sustained-release adjuvant is selected from phosphate polymer, or the mixture or copolymer of phosphate polymer. The suspending agent is selected from sodium CM-cellulose, iodine glycerin, dimethylsilicone oil, etc. The angiogenesis inhibitors are selected from vandetanib, zamestra, sirolimus, etc. The antitumor antibiotics are selected from bleomycin, daunomycin, aclarubicin, etc. The tetrazine drugs are selected from imidazotetrazine, imidazopiperazine, imidazopyridine, etc. The sustained-release composition can decrease markedly systemic reaction of drugs, and enhance selectively therapeutic effects of non-operative treatment.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor sustained-release composition containing angiogenesis inhibitors and
their synergists)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:951286 CAPLUS
DOCUMENT NUMBER: 147:371648
TITLE: Sustained-release composition containing angiogenesis inhibitors and topoisomerase inhibitors and/or tetrazine drugs for treating solid tumors
INVENTOR(S): Sun, Juan; Zhang, Jie; Zou, Huifeng
PATENT ASSIGNEE(S): Jinan Shuaihua Pharmaceutical Science and Technology Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 32pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101020057	A	20070822	CN 2007-10200323	20070323

PRIORITY APPLN. INFO.: CN 2007-10200323 20070323

AB The present invention relates to sustained-release composition (injection and implant) consisting of sustained-release microsphere including anti-tumor effective ingredients 0.1-70, sustained-release excipients 30-99.9, suspending agent 0.0-30 weight%, and solvent. The anti-tumor effective ingredients comprise angiogenesis inhibitors and topoisomerase inhibitors and/or tetrazine drugs. The angiogenesis inhibitors are selected from gefitinib, tarceva, pelitinib, sirolimus, tacrolimus, etc. The topoisomerase inhibitors are selected from camptothecin, lurtotecan, topotecan, irinotecan, etc. The tetrazine drugs are selected from procarbazine, mitozolomide, temozolomide, 4-carboxy temozolomide, etc. The sustained-release composition can inhibit solid tumor growth, and can enhance selectively therapeutic effects.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sustained-release composition containing angiogenesis inhibitors and

topoisomerase inhibitors and/or tetrazine drugs for treating solid tumors)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:619578 CAPLUS

DOCUMENT NUMBER: 147:46112

TITLE: Treatment of cancer and other diseases

INVENTOR(S): Habib, Nabil

PATENT ASSIGNEE(S): Nabil Habib Lab, Lebanon; Vianova Labs, Inc.

SOURCE: PCT Int. Appl., 86pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2007064691	A1	20070607	WO 2006-US45665 20061130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2632903	A1	20070607	CA 2006-2632903 20061130
EP 1968607	A1	20080917	EP 2006-844623 20061130
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			US 2005-741725P P 20051202
			WO 2006-US45665 W 20061130

OTHER SOURCE(S): MARPAT 147:46112

AB The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3β,5α,6α-triol), its production, its use, and to methods of treating neoplasms and other tumors as well as other diseases including hypercholesterolemia, autoimmune diseases, viral diseases (e.g., hepatitis B, hepatitis C, or HIV), and diabetes.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:618533 CAPLUS
DOCUMENT NUMBER: 147:72742
TITLE: Pyrazole urea compounds useful in the treatment of cancer and their preparation
INVENTOR(S): Smith, Roger; Hatoum-Mokdad, Holia N.; Cantin, Louis-David; Bierer, Donald E.; Fu, Wenlang; Nagarathnam, Dhanapalan; Ladouceur, Gaetan; Wang, Yamin; Ogutu, Herbert; Wilhelm, Scott; Taylor, Ian; Reddy, Sanjeeva; Gedrich, Richard; Carter, Chris; Schmitt, Aaron; Zhang, Xiaomei
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 209pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007064872	A2	20070607	WO 2006-US45976	20061201
WO 2007064872	A3	20070809		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
CA 2631746 A1 20070607 CA 2006-2631746 20061201
EP 2044053 A2 20090408 EP 2006-838763 20061201
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
JP 2009518298 T 20090507 JP 2008-543482 20061201
MX 2008006979 A 20090114 MX 2008-6979 20080530
PRIORITY APPLN. INFO.: US 2005-741052P P 20051201
US 2006-861703P P 20061130
WO 2006-US45976 W 20061201
OTHER SOURCE(S): MARPAT 147:72742

GI



I



II

AB Pyrazole urea compds., of formula I pharmaceutical compns. which contain them and methods for treating cancer using them. Compds. of formula I wherein A is (un)substituted (hetero)aryl; L is S and O bound to the 4 or 5 position of pyridyl; R1 is (un)branched C3-6 alkyl, C3-6 cycloalkyl, Me-substituted C3-5 cycloalkyl, CF3 and C1-3 alkylphenyl; R2 is H and Me; R3 and R4 are independently H and C1-6 alkyl; R5, R6 and R7 are independently H, halo, OH, C1-6 alkyl, C1-5 haloalkyl and C1-3 alkoxy, where at least one of R5, R6 and R7 is H; and their pharmaceutically acceptable salts, metabolites, solvates, hydrates, prodrugs, polymorphs, diastereoisomers, stereoisomers and mixture of stereoisomers thereof, are claimed. Example compound II was prepared by addition of 4-(4-amino-3-fluorophenoxy)-N-methylpyridine-2-carboxamide to [3-benzyl-1-(3-fluorophenyl)-1H-pyrazol-5-yl]carbamate. All the invention compds. were evaluated for their anticancer activity. From the assay, it was determined that the invention compds. exhibited IC50 < 10 μM.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of pyrazole urea compds. useful in treatment of cancer)
RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:569280 CAPLUS
DOCUMENT NUMBER: 147:39055
TITLE: Antitumor sustained-release injection containing interstitial hydrolytic agent
INVENTOR(S): Sun, Juan; Zhang, Hongjun; Yu, Jianjiang; Zou, Huifeng
PATENT ASSIGNEE(S): Jinan Kangquan Pharmaceutical Science and Technology Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 30pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent

LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1961862	A	20070516	CN 2006-10201186	20061201
PRIORITY APPLN. INFO.:			CN 2006-10201186	20061201

AB The title antitumor injection consists of sustained-release microsphere and solvent. The sustained-release microsphere includes antitumor drugs selected from interstitial hydrolytic agent such as collagenase, hyaluronidase, muramidase, relaxin, plasmin, gefitinib, erlotinib, and combination of antibiotics and/or antimetabolite drugs. The sustained-release microsphere includes excipients being one or more of polylactic acid and its copolymer, fatty acid-sebacic acid copolymer, etc. The viscosity of suspending agent is 80 cp-3000 cp. The sustained-release microsphere can also be manufactured into sustained-release implant. After intratumoral or peritumoral injection or placement of the sustained-release implant, the drug can be locally released for about 40 days with good inhibitory effect on tumor growth. The sustained-release agent also enhances therapeutic effect on chemotherapy and/or radiotherapy when used in combination.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor sustained-release injection containing interstitial hydrolytic agent)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:569278 CAPLUS
DOCUMENT NUMBER: 147:39054
TITLE: Manufacture of antitumor composition
INVENTOR(S): Sun, Juan; Yu, Jianjiang; Zhang, Hongjun; Liu, Enxiang
PATENT ASSIGNEE(S): Jinan Kangquan Pharmaceutical Science and Technology Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 32pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1961860	A	20070516	CN 2006-10201180	20061201

PRIORITY APPLN. INFO.: CN 2006-10201180 20061201

AB The medicinal composition can be sustained-release injection consisting of sustained-release microsphere and solvent, wherein the sustained-release microsphere includes active ingredients and sustained-release auxiliary materials. The active ingredients can be combination of interstitium hydrolytic agent, and topoisomerase inhibitor and/or tetrazines. The interstitium hydrolytic agent is selected from elastase, trypsin, pepsin, pronase, dispase, bromelains, chymotrypsin, clostripain, fibrinolysin, cathepsin-G, plasminogen activator, collagenase, streptokinase, glycosidase, hyaluronidase, muramidase, relaxin, interferon, brinolase, gefitinib, erlotinib, lapatinib, vatalanib, pelitinib, carboxyaminotriazole, thalidomide, angiostatin, endostatin, imatinib mesilate, avastin, sorafenib, and sutent. The tetrazines can be one or more of imidazotetrazine, imidazopyrazine, imidazopyridine, procarbazine, mitozolomide, temozolomide, 4-carboxytemozolomide, and 3-N-methyl-temozolomide. The topoisomerase inhibitor can be camptothecin, 9-nitro-camptothecin, podophyllotoxin, trihydroxyisoflavone, lurtotecan, topotecan, irinotecan, etoposide, teniposide, adriamycin, amrubicin, detorubicin, esorubicin, rodorubicin, leurubicin, and zorubicin. The

sustained-release microsphere can also be manufactured into sustained-release implant agent, and can locally release drug for about 30-50 days. The medicinal composition can inhibit tumor, and enhance effect of chemotherapy and/or radiotherapy, and other non-surgical therapies when used in combination.

IT 85622-93-1, Temozolomide 85622-93-1D, Temozolomide, 4-Carboxy- or 3-N-Methyl- 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of antitumor composition)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:565405 CAPLUS
DOCUMENT NUMBER: 147:9904
TITLE: Pyrazolyl urea derivatives useful in the treatment of cancer and their preparation
INVENTOR(S): Cantin, Louis-David; Smith, Roger; Chen, Zhi; Hatoum-Mokdad, Holia N.; Mull, Eric
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 159pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007059202	A2	20070524	WO 2006-US44322	20061115
WO 2007059202	A3	20070809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
CA 2629468	A1	20070524	CA 2006-2629468	20061115
EP 1960394	A2	20080827	EP 2006-837652	20061115
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2005-736400P	P 20051115

GI



I

AB Pyrazole urea compds., pharmaceutical compns. which contain them and methods for treating cancer using them. Example compound I was prepared by condensation of [5-tert-butyl-2-(4-fluorophenyl)-2H-pyrazol-3-yl]carbamic acid Ph ester with 4-[2-(2,5-dimethylpyrrol-1-yl)pyridin-4-yloxy]phenylamine; the resulting 1-[5-tert-butyl-2-(4-fluorophenyl)-2H-pyrazol-3-yl]-3-[4-[2-(2,5-dimethylpyrrol-1-yl)pyridin-4-yloxy]phenyl]urea hydrolysis with hydroxylamine to give compound I. All the invention compds. were evaluated for their antiproliferative activity. From the assay, it was determined that the invention compds. exhibited IC50 values of < 10μM.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of pyrazolylurea derivs. useful in treatment of cancer)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:561763 CAPLUS
DOCUMENT NUMBER: 146:494108
TITLE: Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
INVENTOR(S): Plum, Stacy M.; Strawn, Steven J.; Lavallee, Theresa M.; Sidor, Carolyn F.; Fogler, William E.; Treston, Anthony M.
PATENT ASSIGNEE(S): Entremed, Inc., USA
SOURCE: PCT Int. Appl., 49pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007059111	A2	20070524	WO 2006-US44152	20061114
WO 2007059111	A3	20090514		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20070185069	A1	20070809	US 2006-599997	20061114
PRIORITY APPLN. INFO.:			US 2005-736220P P	20051114
			US 2006-788354P P	20060331

AB The present invention relates generally to methods and compns. of treating

disease characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering antiangiogenic agents in combination with chemotherapeutic agents. More specifically, the present invention relates to a methods and compns. of treating diseases characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering 2-methoxyestradiol, in combination with chemotherapeutic agents.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-angiogenic activity of 2-methoxyestradiol and other estradiols in combination with anti-cancer agents)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:537782 CAPLUS
DOCUMENT NUMBER: 146:514717
TITLE: Combination treatment of cancer comprising EGFR/HER2

inhibitors

INVENTOR(S): Solca, Flavio; Amelsberg, Andree; Stehle, Gerd; Van Meel, Jacobus C. A.; Baum, Anke

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG

SOURCE: PCT Int. Appl., 107pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007054551	A1	20070518	WO 2006-EP68314	20061109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2629249	A1	20070518	CA 2006-2629249	20061109
EP 1948180	A1	20080730	EP 2006-819380	20061109
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009515852	T	20090416	JP 2008-539441	20061109
PRIORITY APPLN. INFO.:			EP 2005-110669 A	20051111
			WO 2006-EP68314 W	20061109

OTHER SOURCE(S): MARPAT 146:514717

GI



I

AB The invention discloses a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amts. of (1) a compound I (Ra = benzyl, 1-phenylethyl, 3-chloro-4-fluorophenyl; Rb = H, C1-4 alkyl; Rc = cyclopropylmethoxy, cyclobutoxy, etc.; Rd = dimethylamino, N-cyclopropyl-N-methylamino, etc.); and (2) at least a further chemotherapeutic agent; optionally in combination with radiotherapy, radioimmunotherapy and/or tumor resection by surgery. The invention further discloses corresponding medicaments and the preparation thereof.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(EGFR/HER2 inhibitor combination treatment for cancer)
RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:1202105 CAPLUS
DOCUMENT NUMBER: 146:32919
TITLE: Antitumor sustained-release injection containing vascular inhibitor and its synergistic agent from topoisomerase inhibitors and/or tetrazine compounds
INVENTOR(S): Kong, Qingxia
PATENT ASSIGNEE(S): Jinan Shuaihua Pharmaceutical Science and Technology Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 32pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1857205	A	20061108	CN 2006-10200204	20060306

PRIORITY APPLN. INFO.: CN 2006-10200204 20060306

AB The sustained-release injection is comprised of (A) sustained-release microsphere comprising antitumor effective constituent 0.5-60, sustained-release adjuvant 41-99.9% and suspending agent 0.0-30.0%; and (B) solvent. The antitumor effective constituent is selected from vascular inhibitor and/or its synergistic agent which is selected from topoisomerase inhibitors and/or tetrazine compds. Said vascular inhibitors are selected from gefitinib, tarceva, lapatinib, N-(4-chlorophenyl)-4-(pyridin-4-yl-methyl)phtalazin-1-amine, etc. Said topoisomerase inhibitors are selected from one of camptothecin, hydroxycamptothecin, lurtotecan, topotecan, irinotecan, etc., or the mixture thereof. Said tetrazine compds. are selected from one of procarbazine, mitozolomide, 4-carboxy temozolomide, temozolomide, or the mixture thereof. The sustained-release adjuvant is selected from one of (a) polylactic acid; (b) polyglycolic acid-hydroxy acetic acid copolymer; (c) polifeprosan; (d) ethene-vinyl acetate copolymer; (e) difatty acid-sebacic acid copolymer; (f) poly(erucic acid dimer-sebacic acid) copolymer; (g) poly(fumaric acid-sebacic acid) copolymer; (h) xylitol, oligosaccharide, chondroitin, chitin, hyaluronic acid, collagens, etc.; or the mixture thereof. The suspending agent is one of (a) 0.5-3.0% (sodium) CM-cellulose; (b) 5-15% mannitol; (c) 5-15% sorbitol; (d) 0.1-1.5% surfactant; (e) 0.1-0.5% tween 20; (f) (iodine) glycerin, dimethicone, propylene glycol, or carbomer; (g) 0.5-5% sodium CM-cellulose + 0.1-0.5% tween 80; (h) 5-20% mannitol + 0.1-0.5% tween 80; or (i) 0.5-5% sodium CM-cellulose + 5-20% sorbitol + 0.1-0.5% tween 80.

IT 85622-93-1, Temozolomide 85622-93-1D, Temozolomide, carboxy derivs. 212141-54-3, Vatalanib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor sustained-release injection containing vascular inhibitor and synergistic agent from topoisomerase inhibitors and/or tetrazine compds.)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:981749 CAPLUS
DOCUMENT NUMBER: 145:335928
TITLE: Preparation of 1,5-dihydro-3-hydroxy-2H-pyrrol-2-ones as Mdm2 protein modulators
INVENTOR(S): Weber, Lutz
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 11pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102005012681	A1	20060921	DE 2005-102005012681	20050318

PRIORITY APPLN. INFO.: DE 2005-102005012681 20050318
OTHER SOURCE(S): CASREACT 145:335928; MARPAT 145:335928
GI



I II

AB Title compds. I [R1, R2 = cycloalkyl, heteroaryl, aryl, etc.; R3 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, coupling of carboxylic acid II [X = OH] and 2-methoxyethylamine afforded amide II [X = NHCH2CH2OCH3]. Compds. I are are noted as Mdm2 protein modulators (no data provided).

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments with; preparation of 3-hydroxy-2H-pyrrolones as Mdm2 protein modulators)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 31 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:976176 CAPLUS
DOCUMENT NUMBER: 145:335951
TITLE: Tetrahydroisoquinolin-1-ones as HDM2 ligands, their preparation, pharmaceutical compositions, and use for the treatment of cancer
INVENTOR(S): Weber, Lutz
PATENT ASSIGNEE(S): Germany
SOURCE: PCT Int. Appl., 42pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006097323	A1	20060921	WO 2006-EP2471	20060317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090068144	A1	20090312	US 2008-909014	20080623
PRIORITY APPLN. INFO.:			DE 2005-102005012680A	20050318
			WO 2006-EP2471 W	20060317

OTHER SOURCE(S): CASREACT 145:335951; MARPAT 145:335951
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. according to formula I, which are HDM2 protein ligands, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy. In compds. I, R1 is selected from (un)substituted morpholinyl, (un)substituted pyrrolidinyl, (un)substituted piperazinyl, OR5, and NR5R6, where R5 and R6 are independently selected from H, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; R2 and R3 are independently selected from aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is selected from H, OH, halo, nitro, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, and NR7R8, where R7 and R8 are independently selected from H, lower alkyl, lower alkoxyalkyl, heterocyclyl, aryl, and heteroaryl. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, optionally in combination with a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of cancer. Condensation of 4-chlorobenzaldehyde with 4-chlorobenzylamine followed by heterocyclization with homophthalic anhydride gave isoquinolinonecarboxylic acid II, which was amidated with 2-methoxyethylamine to give isoquinolinone III. The compds. of the invention are ligands of HDM2 (no data).

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of tetrahydroisoquinolinones as HDM2 ligands for the treatment of cancer)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 32 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:845730 CAPLUS
DOCUMENT NUMBER: 145:278268
TITLE: Antitumor compositions containing antiangiogenic agents and aldesleukin for synergistic effect
INVENTOR(S): Aukerman, Sharon Lea; Denis-Mize, Kimberly; Elias, Laurence; Jallal, Bahija; Menezes, Daniel; Witherell, Gary W.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 104pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006089150	A2	20060824	WO 2006-US5720	20060217
WO 2006089150	A3	20061102		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006214138	A1	20060824	AU 2006-214138	20060217
CA 2598448	A1	20060824	CA 2006-2598448	20060217

EP 1853302 A2 20071114 EP 2006-735400 20060217
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
JP 2008530239 T 20080807 JP 2007-556337 20060217
MX 2007010037 A 20080215 MX 2007-10037 20070817
IN 2007KN03324 A 20080321 IN 2007-KN3324 20070907
KR 2007108909 A 20071113 KR 2007-721118 20070914
CN 101146549 A 20080319 CN 2006-80009316 20070921
PRIORITY APPLN. INFO.: US 2005-654341P P 20050218
WO 2006-US5720 W 20060217

OTHER SOURCE(S): MARPAT 145:278268

AB The present invention relates to combination therapies with IL-2 compns. and antiangiogenic agents for the treatment of cancer. Further provided are methods of alleviating toxicities and increasing the efficacy associated with the administration of IL-2 compns. or antiangiogenic compns.

IT 85622-93-1P 212141-54-3P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor compns. containing antiangiogenic agents and aldesleukin for synergistic effect)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:372182 CAPLUS
DOCUMENT NUMBER: 144:495317
TITLE: Anticancer implantation composition containing angiogenesis inhibitor and antitumor agent
INVENTOR(S): Kong, Qingzhong; Sun, Juan; Yu, Jianjiang
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 19 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1733302	A	20060215	CN 2005-10044379	20050805

PRIORITY APPLN. INFO.: CN 2005-10044379 20050805

AB The title anticancer implantation composition comprises an angiogenesis inhibitor, an antitumor agent (plant alkaloids, platinum compds., tetrazines, and/or topoisomerase inhibitors), and pharmaceutical auxiliary materials. The auxiliary materials are biocompatible and degradable polymer which can slowly release the anticancer medicines at the tumor site during the degradation and absorption process. This composition can be placed at the tumor site to reduce systemic toxic reaction of the drugs, to increase the drug concentration selectively at the tumor site, and to improve the therapeutic effect of non-operative therapy, such as chemotherapy and radiotherapy.

IT 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticancer implantation composition containing angiogenesis inhibitor and anticancer medicine)

RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



IT 85622-93-1, Temozolomide
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tartrate salt)
RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



L5 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:167588 CAPLUS
DOCUMENT NUMBER: 144:254148
TITLE: Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Munzert, Gerd; Steegmaier, Martin; Baum, Anke
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018182	A1	20060223	WO 2005-EP8623	20050809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060058311	A1	20060316	US 2005-189540	20050726
AU 2005274384	A1	20060223	AU 2005-274384	20050809
CA 2576269	A1	20060223	CA 2005-2576269	20050809
EP 1827441	A1	20070905	EP 2005-770228	20050809
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
CN 101039673	A	20070919	CN 2005-80035272	20050809
JP 2008509948	T	20080403	JP 2007-526349	20050809
BR 2005014357	A	20080610	BR 2005-14357	20050809
ZA 2007000280	A	20080528	ZA 2007-280	20070110
IN 2007DN00888	A	20070803	IN 2007-DN888	20070202
MX 2007001853	A	20070328	MX 2007-1853	20070214
KR 2007050478	A	20070515	KR 2007-705955	20070314
PRIORITY APPLN. INFO.:			EP 2004-19361 A	20040814
			EP 2004-19448 A	20040817
			WO 2005-EP8623 W	20050809

OTHER SOURCE(S): CASREACT 144:254148; MARPAT 144:254148
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of aminopteridinones I, which are useful for the treatment of diseases which involve cell proliferation. In compds. I, R1 and R2 are independently selected from H and (un)substituted C1-6 alkyl, or R1 and R2 together form a 2- to 5-membered alkylene bridge, optionally containing 1 or 2 heteroatoms; R3 is (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-14 aryl, etc.; R4 is H, OH, CN, halo, (un)substituted amino, (un)substituted C1-6 alkyl, C1-5 alkoxy, etc.; L is (un)substituted C2-10 alkylene, (un)substituted C2-10 alkenylene, (un)substituted C6-14 arylene, etc.; R5 is (un)substituted morpholinyl, (un)substituted piperidinyl, (un)substituted piperazinyl, (un)substituted piperazinylcarbonyl, (un)substituted pyrrolidinyl, (un)substituted thiomorpholinyl, etc.; n is 0 or 1; and m is 1 or 2; including tautomers, stereoisomers, salts, solvates, polymorphs, and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, at least one other therapeutic agent, optionally with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. for the treatment of diseases which involve cell

proliferation, migration or apoptosis of cancer cells, or angiogenesis. Esterification of (R)-2-aminobutyric acid and reductive condensation with cyclopentanone gave cyclopentylamine II, which underwent regioselective substitution of 2,4-dichloro-5-nitropyrimidine and reductive heterocyclization to form pteridinone III. N-Methylation of III followed by substitution with 4-amino-3-methoxybenzoic acid and amidation with 1-methyl-4-aminopiperidine resulted in the formation of aminopteridinone IV. A combination of suboptimal doses of irinotecan and compound IV shows an additive/synergistic effect in a human colon carcinoma model and is well tolerated. Meanwhile, compound IV acts at least additively with docetaxel in a human non-small cell lung carcinoma model and not antagonistically with gemcitabine in a human adenocarcinoma model.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 35 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1290072 CAPLUS
DOCUMENT NUMBER: 144:46998
TITLE: The x-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compositions for antitumor drug design
INVENTOR(S): Yaffe, Michael B.; Clapperton, Julie A.; Manke, Isaac A.; Lowery, Drew M.; Ho, Timmy; Haire, Lesley F.; Smerdon, Stephen J.
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA
SOURCE: PCT Int. Appl., 360 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115454	A2	20051208	WO 2005-US15981	20050509
WO 2005115454	A3	20071115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
AU 2005247346	A1	20051208	AU 2005-247346	20050509
CA 2569003	A1	20051208	CA 2005-2569003	20050509
EP 1773389	A2	20070418	EP 2005-780060	20050509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2007537164	T	20071220	JP 2007-511664	20050509
US 20090143997	A1	20090604	US 2008-229740	20080826
PRIORITY APPLN. INFO.:			US 2004-569131P	P 20040507
			US 2005-126022	B3 20050509
			WO 2005-US15981	W 20050509

AB The present invention relates to compds. (e.g., peptidomimetics and non-peptides) that treat, prevent or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a BRCT domain-BACH1 phosphopeptide complex.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(x-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compns. for antitumor drug design)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide,

3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 36 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1239173 CAPLUS
DOCUMENT NUMBER: 143:477963
TITLE: Preparation of pyrazolyl urea derivatives as TrkA kinase inhibitors useful in the treatment of cancer
INVENTOR(S): Lee, Wendy; Ladouceur, Gaetan; Dumas, Jacques; Smith, Roger; Ying, Shihong; Wang, Gan; Chen, Zhi; Liu, Qingjie; Mokdad, Holia Hatoum
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005110994	A2	20051124	WO 2005-US15106		20050502
WO 2005110994	A3	20060202			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2564325	A1	20051124	CA 2005-2564325		20050502
EP 1751139	A2	20070214	EP 2005-778149		20050502
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
CN 101010315	A	20070801	CN 2005-80022290		20050502
JP 2007535565	T	20071206	JP 2007-511073		20050502
MX 2006012394	A	20070131	MX 2006-12394		20061026
US 20080214545	A1	20080904	US 2008-579093		20080115
PRIORITY APPLN. INFO.:			US 2004-566445P	P	20040430
			WO 2005-US15106	W	20050502

OTHER SOURCE(S): CASREACT 143:477963; MARPAT 143:477963
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1-2 = H, alkyl, halo; A = Ph, pyridine, pyrimidine; B = phenylene, naphthylene; L = O, S, CH2; M = Ph, pyridine, pyrimidine; n = 0-1; X = O, SO2, etc.; Y = alkoxy, oxycarbonyl, amino, etc.] are prepared For instance, II is prepared from 4-[3-tert-butyl-5-[N'-[4-(pyridin-4-yloxy)phenyl]ureido]pyrazol-1-yl]benzoic acid Me ester (preparation given) and 2-(pyrrolidin-1-yl)ethylamine (DCE, AlMe3, 80°, 16 h). Compds. of the invention show significant inhibition of TrkA kinase (IC50 < 1 μM). I are useful for the treatment of cancer.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted pyrazolylurea derivs. useful for cancer treatment)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:409543 CAPLUS
DOCUMENT NUMBER: 142:457053
TITLE: Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy
INVENTOR(S): Lacasse, Eric; McManus, Daniel
PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042558	A1	20050512	WO 2004-CA1902	20041029

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG

US 20050148535	A1	20050707	US 2004-975974		20041028
CA 2542904	A1	20050512	CA 2004-2542904		20041029
EP 1682565	A1	20060726	EP 2004-789809		20041029
R: DE, FR, GB					
JP 2007510408	T	20070426	JP 2006-537024		20041029
PRIORITY APPLN. INFO.:			US 2003-516192P	P	20031030
			WO 2004-CA1902	W	20041029

AB The invention provides nucleobase oligomers and oligonucleotide duplexes that inhibit expression of an IAP (inhibitor of apoptosis protein), and methods for using them to induce apoptosis in a cell. Specifically, the invention provides nucleic acid sequences for siRNAs and shRNAs that target human XIAP, HIAP-1 or HIAP-2 genes. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compns. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent. RNAi sequences and vectors producing shRNA (short hairpin RNA) were transfected into HeLa cells and evaluated for their effect on XIAP, cIAP-1, or cIAP-2 protein levels. XIAP protein could also be reduced by RNAi clones in transfected breast cancer cell line MDA-MB-231. In addition, cell survival was reduced in XIAP RNAi transfected breast cancer cell line after the transfected cells were treated with TRAIL (tumor necrosis factor-related apoptosis inducing ligand).

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:409357 CAPLUS
DOCUMENT NUMBER: 142:457052
TITLE: Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent
INVENTOR(S): Lacasse, Eric; McManus, Daniel; Durkin, Jon P.
PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042030	A1	20050512	WO 2004-CA1900	20041029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050119217	A1	20050602	US 2004-975790	20041028
AU 2004284855	A1	20050512	AU 2004-284855	20041029
CA 2542884	A1	20050512	CA 2004-2542884	20041029
EP 1691842	A1	20060823	EP 2004-789807	20041029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004015779	A	20061226	BR 2004-15779		20041029
CN 1901939	A	20070124	CN 2004-80039601		20041029
JP 2007509861	T	20070419	JP 2006-537023		20041029
ZA 2006003399	A	20070926	ZA 2006-3399		20041029
MX 2006004920	A	20070216	MX 2006-4920		20060502
IN 2006MN00614	A	20070420	IN 2006-MN614		20060526
NO 2006002420	A	20060731	NO 2006-2420		20060529
KR 2006127393	A	20061212	KR 2006-710619		20060530
PRIORITY APPLN. INFO.:			US 2003-516263P	P	20031030
			WO 2004-CA1900	W	20041029

AB The invention claims the use of an antisense oligomer to human XIAP, IAP-1 or IAP-2 genes and a chemotherapeutic agent, and compns. and kits thereof, for the treatment of proliferative diseases. The invention further claims sequences for nucleobase oligomers that are antisense IAP (inhibitor of apoptosis protein) oligomers. The antisense IAP nucleobase oligomers specifically hybridize with polynucleotides encoding an IAP and reduce the amount of an IAP protein produced in a cell. Thus by reducing the IAP protein, the invention provides methods for inducing cancer cells to undergo apoptosis and for overriding anti-apoptotic signals in cancer cells. As an example of the invention, mice with s.c. H460 human lung carcinoma xenografts were injected intratumorally with XIAP antisense mixed-base 2'-O-Me RNA oligonucleotides (C5 and/or G4) and the drug vinorelbine. At the end of the 24 d treatment period, the mean relative tumor growth was reduced .apprx.70% in treated mice. The inhibition of tumor growth was correlated with down-regulation of human XIAP protein expression and an increased number of dead cells. The mice did not show any signs of cytotoxicity such as body weight loss.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with chemotherapeutic agent)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:371085 CAPLUS
DOCUMENT NUMBER: 142:423814
TITLE: Combination therapy for cancer and viral infections
INVENTOR(S): Moller, Niels Peter Hundahl; Skak, Kresten; Mueller, Jorn Roland
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037306	A1	20050428	WO 2004-DK683	20041008
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2542662	A1	20050428	CA 2004-2542662	20041008
EP 1680138	A1	20060719	EP 2004-762902	20041008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007508332	T	20070405	JP 2006-534587	20041008
MX 2006004199	A	20060628	MX 2006-4199	20060412

US 20070031374	A1	20070208	US 2006-404733		20060414
US 20080206192	A1	20080828	US 2008-112452		20080430
PRIORITY APPLN. INFO.:			DK 2003-1529	A	20031017
			US 2003-513422P	P	20031022
			DK 2004-707	A	20040504
			US 2004-569566P	P	20040510
			WO 2004-DK683	W	20041008
			US 2006-404733	A1	20060414

AB The invention provides combination treatments with IL-21, analogs and derivs. thereof for the treatment of cancer and viral infection.

IT 85622-93-1, Temozolomide 212141-54-3, PTK787
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy for cancer and viral infections)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:283298 CAPLUS
DOCUMENT NUMBER: 142:349042
TITLE: Combinations of chlorpromazine compounds and antiproliferative drugs for the treatment of neoplasms
INVENTOR(S): Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027842	A2	20050331	WO 2004-US30368	20040916
WO 2005027842	A3	20051222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004273910	A1	20050331	AU 2004-273910	20040916
CA 2538570	A1	20050331	CA 2004-2538570	20040916
EP 1670477	A2	20060621	EP 2004-788798	20040916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014568	A	20061107	BR 2004-14568	20040916
CN 1878556	A	20061213	CN 2004-80033294	20040916
JP 2007505914	T	20070315	JP 2006-527024	20040916
MX 2006003066	A	20060620	MX 2006-3066	20060317
NO 2006001325	A	20060606	NO 2006-1325	20060323
KR 2007012618	A	20070126	KR 2006-707244	20060414
PRIORITY APPLN. INFO.:			US 2003-504310P P	20030918
			WO 2004-US30368 W	20040916

OTHER SOURCE(S): MARPAT 142:349042

AB The invention discloses a method for treating a patient having a cancer or other neoplasm by administering chlorpromazine or a chlorpromazine analog and an antiproliferative agent simultaneously or within 14 days of each other in amts. sufficient to treat the patient.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorpromazine compound-antiproliferative drug antitumor combination)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



L5 ANSWER 41 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:99470 CAPLUS
DOCUMENT NUMBER: 142:197889
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases
INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009961	A2	20050203	WO 2004-US23500	20040722
WO 2005009961	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004259760	A1	20050203	AU 2004-259760		20040722
CA 2532865	A1	20050203	CA 2004-2532865		20040722
US 20050038080	A1	20050217	US 2004-895985		20040722
EP 1663978	A2	20060607	EP 2004-786091		20040722
EP 1663978	B1	20071128			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004012219	A	20060822	BR 2004-12219		20040722
CN 1856469	A	20061101	CN 2004-80021091		20040722
JP 2006528196	T	20061214	JP 2006-521221		20040722
ES 2297490	T3	20080501	ES 2004-786091		20040722
ZA 2006000609	A	20070530	ZA 2006-609		20060120
KR 2006052866	A	20060519	KR 2006-701558		20060123
MX 2006000860	A	20060720	MX 2006-860		20060123
IN 2006DN00402	A	20070824	IN 2006-DN402		20060123
NO 2006000870	A	20060407	NO 2006-870		20060222
PRIORITY APPLN. INFO.:			US 2003-489102P	P	20030723
			US 2004-540326P	P	20040202
			WO 2004-US23500	W	20040722

OTHER SOURCE(S): CASREACT 142:197889

GI



I

AB Title compound I is prepared I and salts thereof is prepared in several steps from 3-fluoro-4-nitrophenol, 4-chloro-N-methylpyridine-2-carboxamide and 4-chloro-3-(trifluoromethyl)phenylisocyanate. I inhibits PDGFR tyrosine kinase with IC50 = 83 nM. I is useful for the treatment of, e.g., inflammation and as an antiproliferative agent.

IT 85622-93-1, Temozolomide 212141-54-3, PTK 787
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:965067 CAPLUS
DOCUMENT NUMBER: 141:406039
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004233576	A1	20041111	AU 2004-233576	20040424
CA 2523868	A1	20041111	CA 2004-2523868	20040424
EP 1622619	A2	20060208	EP 2004-729366	20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424
JP 2006524634	T	20061102	JP 2006-500099	20040424
MX 2005011656	A	20051215	MX 2005-11656	20051028
NO 2005005605	A	20051128	NO 2005-5605	20051128

PRIORITY APPLN. INFO.:		
EP 2003-9587	A	20030429
EP 2004-508	A	20040113
EP 2004-1171	A	20040121
WO 2004-EP4363	W	20040424

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination prepns. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:756710 CAPLUS
DOCUMENT NUMBER: 141:277628
TITLE: Preparation of ureidophenoxycyanopyridines as anticancer drugs.
INVENTOR(S): Scott, William J.; Dumas, Jacques; Boyer, Stephen; Lee, Wendy; Chen, Yuanwei; Phillips, Barton; Verma, Sharad; Chen, Jianqing; Chen, Zhi; Fan, Jianmei; Raudenbush, Brian; Redman, Aniko; Yi, Lin; Zhu, Qingming
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078747	A1	20040916	WO 2004-US6286	20040301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040235829	A1	20041125	US 2004-788029	20040227
US 7557129	B2	20090707		
AU 2004217977	A1	20040916	AU 2004-217977	20040301
CA 2517361	A1	20040916	CA 2004-2517361	20040301
US 20040229937	A1	20041118	US 2004-789446	20040301
US 20050032798	A1	20050210	US 2004-788405	20040301
US 20050038031	A1	20050217	US 2004-788426	20040301
EP 1599467	A1	20051130	EP 2004-716144	20040301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004007897	A	20060301	BR 2004-7897	20040301
JP 2006519264	T	20060824	JP 2006-508977	20040301
CN 1839126	A	20060927	CN 2004-80011547	20040301
IN 2005DN03802	A	20070824	IN 2005-DN3802	20050826
PRIORITY APPLN. INFO.:			US 2003-450323P P	20030228
			US 2003-450324P P	20030228
			US 2003-450348P P	20030228
			WO 2004-US6286 A	20040301

OTHER SOURCE(S): CASREACT 141:277628; MARPAT 141:277628

GI



I



II

AB Title compds. [I; A = (substituted) pyridinyl, naphthyl, 8-10 membered bicyclic heteroaryl, heterocyclyl, carbocyclyl; B = (substituted) phenylene, naphthylenediyl; L = O, S; m = 0-3; R2 = alkyl, haloalkyl, alkoxy, N-oxo, N-hydroxyl, were prepared Thus, 2-trifluoromethyl-4-pyridylamine was stirred 20 h with carbonyldiimidazole in CH2Cl2; 4-(4-amino-3-fluorophenoxy)pyridine-2-carbonitrile (preparation given) was added followed by stirring for 1 day to give 75% title compound (II). I inhibited c-RAF-1 kinase with IC50 = 7.86 nM to >1600 nM.

IT 85622-93-1, Temozolomide 212141-54-3, Vatalanib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)

RN 85622-93-1 CAPLUS
CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:20498 CAPLUS
DOCUMENT NUMBER: 140:71008
TITLE: Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor
INVENTOR(S): Dugan, Margaret Han
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002485	A1	20040108	WO 2003-EP6848	20030627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2490130	A1	20040108	CA 2003-2490130	20030627
AU 2003249895	A1	20040119	AU 2003-249895	20030627
BR 2003012283	A	20050412	BR 2003-12283	20030627
EP 1545527	A1	20050629	EP 2003-761547	20030627
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1662239	A	20050831	CN 2003-814922	20030627
CN 100355423	C	20071219		
JP 2005531622	T	20051020	JP 2004-516730	20030627
US 20060211674	A1	20060921	US 2005-518989	20050721
PRIORITY APPLN. INFO.:			US 2002-392589P P	20020628
			WO 2003-EP6848 W	20030627
OTHER SOURCE(S):	MARPAT 140:71008			

GI



I

AB The invention relates to pharmaceutical combination which comprises (a) a vasculostatic compound, (b) an alkylating agent and (c) optionally at least one pharmaceutically acceptable carrier to simultaneous, sep. or sequential use for the treatment of a tumor disease. An example combination is PTK787 (I) and lomustine.

IT 85622-93-1, Temozolomide 212141-54-3, 1-Phthalazinamine, N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor)

RN 85622-93-1 CAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- (CA INDEX NAME)



RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:31:58 ON 15 JUL 2009)

FILE 'REGISTRY' ENTERED AT 15:32:43 ON 15 JUL 2009
E VATALANIB/CN
L1 1 S E3
L2 1 S TEMOZOLOMIDE/CN

FILE 'CAPLUS' ENTERED AT 15:38:47 ON 15 JUL 2009
L3 269 S L1
L4 1548 S L2
L5 44 S L3 AND L4
L6 800162 S CANCER OR TUMOR?
L7 38 S L5 AND L6

10/518,989

=>